BACKGROUND: Decompressive hemicraniectomy (DHC) reduces mortality and improves outcome after malignant middle cerebral artery (MCA) infarction but leaves a high number of survivors severely disabled. Attitudes among physicians toward the degree of disability that is considered acceptable and the impact of aphasia may play a major role in treatment decisions. METHODS: DESTINY-S is a multicenter, international, cross-sectional survey among 1,860 physicians potentially involved in the treatment of malignant MCA infarction. Questions concerned the grade of disability, the hemisphere of the stroke, and the preferred treatment for malignant MCA infarction. RESULTS: mRS scores of 3 or better were considered acceptable by the majority of respondents (79.3%). Only few considered a mRS score of 5 still acceptable (5.8%). A mRS score of 4 was considered acceptable by 38.0%. Involved hemisphere (dominant vs. non-dominant) was considered a major clinical symptom influencing treatment decisions in 47.7% of respondents, also reflected by significantly different rates for DHC as preferred treatment in dominant versus non-dominant hemispheric infarction (46.9 vs. 72.9%). Significant differences in acceptable disability and treatment decisions were found among geographic regions, medical specialties, and respondents with different work experiences. CONCLUSION: Little consensus exists among physicians regarding acceptable outcome and therapeutic management after malignant MCA infarction, and physician's recommendations do not correlate with available evidence. We advocate for a decision-making process that balances scientific evidence, patient preference, and clinical expertise.
BACKGROUND: Decompressive hemicraniectomy (DHC) reduces mortality and improves outcome after malignant middle cerebral artery (MCA) infarction but leaves a high number of survivors severely disabled. Attitudes among physicians toward the degree of disability that is considered acceptable and the impact of aphasia may play a major role in treatment decisions. METHODS: DESTINY-S is a multicenter, international, cross-sectional survey among 1,860 physicians potentially involved in the treatment of malignant MCA infarction. Questions concerned the grade of disability, the hemisphere of the stroke, and the preferred treatment for malignant MCA infarction. RESULTS: mRS scores of 3 or better were considered acceptable by the majority of respondents (79.3%). Only few considered a mRS score of 5 still acceptable (5.8%). A mRS score of 4 was considered acceptable by 38.0%. Involved hemisphere (dominant vs. non-dominant) was considered a major clinical symptom influencing treatment decisions in 47.7% of respondents, also reflected by significantly different rates for DHC as preferred treatment in dominant versus non-dominant hemispheric infarction (46.9 vs. 72.9%). Significant differences in acceptable disability and treatment decisions were found among geographic regions, medical specialties, and respondents with different work experiences. CONCLUSION: Little consensus exists among physicians regarding acceptable outcome and therapeutic management after malignant MCA infarction, and physician's recommendations do not correlate with available evidence. We advocate for a decision-making process that balances scientific evidence, patient preference, and clinical expertise.
Authors: K Vahedi; L Benoist; A Kurtz; J Mateo; A Blanquet; M Rossignol; P Amarenco; A Yelnik; E Vicaut; D Payen; M G Bousser Journal: J Neurol Neurosurg Psychiatry Date: 2005-08 Impact factor: 10.154
Authors: Georg Leonhardt; Hans Wilhelm; Arnd Doerfler; Christiane E Ehrenfeld; Beate Schoch; Friedhelm Rauhut; Andreas Hufnagel; Hans Christoph Diener Journal: J Neurol Date: 2002-10 Impact factor: 4.849
Authors: Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke Journal: Stroke Date: 2007-08-09 Impact factor: 7.914
Authors: Nils Hecht; Hermann Neugebauer; Ingo Fiss; Alexandra Pinczolits; Peter Vajkoczy; Eric Jüttler; Johannes Woitzik Journal: J Cereb Blood Flow Metab Date: 2017-06-30 Impact factor: 6.200
Authors: Kelly L Sloane; Julie J Miller; Amanda Piquet; Brian L Edlow; Eric S Rosenthal; Aneesh B Singhal Journal: J Stroke Cerebrovasc Dis Date: 2022-01-07 Impact factor: 2.136
Authors: Hermann Neugebauer; Matthias Schnabl; Dorothée Lulé; Peter U Heuschmann; Eric Jüttler Journal: Neurocrit Care Date: 2017-04 Impact factor: 3.210